We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Novel Saliva Collection Device Keeps Analytes Stable at Ambient Temperatures for Weeks

By LabMedica International staff writers
Posted on 27 Feb 2023
Print article
Image: The SDNA Saliva Collection Device has received FDA 510(k) Class II Medical Device Clearance (Photo courtesy of Spectrum Solutions)
Image: The SDNA Saliva Collection Device has received FDA 510(k) Class II Medical Device Clearance (Photo courtesy of Spectrum Solutions)

Blood-based diagnostics have been the norm since a long time. However, in the new era of healthcare, providers have adopted salivary collection and preservation to detect viral infections. The process of collecting saliva can make a huge diagnostic difference. Selecting the wrong saliva collection device can create and increase critical failure points. In order to incorporate the use of saliva into molecular diagnostic testing protocols or implement actual real-world mass-testing in scalable scenarios, there is a need for a studied, proven, validated, and supported system that eliminates the risk of exposure and a device that can enhance test precision, sensitivity, and assay reproducibility. Now, a novel saliva collection device is setting new standards of care in testing, managing, and treating diseases.

The SDNA Saliva Collection Device from Spectrum Solutions (Salt Lake City, UT, USA) has the ability to maximize detection at the lowest levels and neutralize viruses within 10-seconds of collection to mitigate unnecessary viral exposure. The company’s patented preservation media keeps analytes stable for several weeks at ambient temperatures, ensuring safe, easy, and secure specimen storage and transport. The SDNA kits do not have any special storage or transport temperature-control requirements for collected saliva samples and eliminate the need for UN3373 biohazard shipping designation. The U.S. Food and Drug Administration (FDA) has granted 510(k) Class II clearance to the SDNA saliva collection device as a microbial nucleic acid storage and stabilization device.

“This 510(k) clearance and certification as an IVD molecular diagnostic device enables physicians, hospitals, researchers and others to leverage our SDNA Saliva Collection Device in a broad array of FDA approved and LDT diagnostic testing applications,” said Stephen Fanning, CEO at Spectrum Solutions. “Those conducting screening and diagnostic tests can confidently and safely expand access and opportunity incorporating saliva as a primary or alternative biomaterial into their existing testing protocols.

Related Links:
Spectrum Solutions

Gold Member
Chagas Disease Test
CHAGAS Cassette
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Hemoglobin/Haptoglobin Assay
IDK Hemoglobin/Haptoglobin Complex ELISA
New
Chagas Disease Test
LIAISON Chagas

Print article

Channels

Clinical Chemistry

view channel
Image: The GlycoLocate platform uses multi-omics and advanced computational biology algorithms to diagnose early-stage cancers (Photo courtesy of AOA Dx)

AI-Powered Blood Test Accurately Detects Ovarian Cancer

Ovarian cancer ranks as the fifth leading cause of cancer-related deaths in women, largely due to late-stage diagnoses. Although over 90% of women exhibit symptoms in Stage I, only 20% are diagnosed in... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: The new algorithms can help predict which patients have undiagnosed cancer (Photo courtesy of Adobe Stock)

Advanced Predictive Algorithms Identify Patients Having Undiagnosed Cancer

Two newly developed advanced predictive algorithms leverage a person’s health conditions and basic blood test results to accurately predict the likelihood of having an undiagnosed cancer, including ch... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.